Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer.

Pengfei CuiDi HuangZhaozhen WuHaitao TaoSujie ZhangJunxun MaZhefeng LiuJinliang WangZiwei HuangShixue ChenXuan ZhengYi Hu

Published in: Therapeutic advances in medical oncology (2020)

CIP is associated with enhanced PD-1/PD-L1 inhibitor efficacy in NSCLC patients. Grade 1-2 pneumonitis and the radiological features of hypersensitivity and cryptogenic organizing pneumonia (COP) may be signs of enhanced ICI efficacy. However, further studies with larger numbers of patients and longer follow-up times are needed to validate our findings.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
small cell lung cancer
prognostic factors
patient reported outcomes
interstitial lung disease